QuantHealth launches Katina: AI-powered platform for clinical trial optimisation

QuantHealth, a startup specialising in AI-powered clinical trial design, has unveiled a significant enhancement to its platform with the introduction of Katina. This cutting-edge tool utilises artificial intelligence to simulate clinical trials on a large scale, aiming to expedite, de-risk, and optimise drug development processes. The launch of Katina represents a transformative phase in clinical trial optimisation, leveraging AI and extensive real-world patient data. This innovative tool has the potential to revolutionise the design and execution of clinical trials, ultimately leading to faster, more efficient drug development and improved patient outcomes.

Katina introduces an AI-guided workflow for clinical researchers, simulating hundreds of thousands of potential trial protocol combinations involving patient groups, treatment parameters, and various endpoints. This comprehensive approach is designed to enhance the probability of trial success while considering operational and commercial factors. Key benefits of Katina include the automation of protocol generation, eliminating the need for time-consuming manual simulations. 

Leveraging QuantHealth's proprietary AI technology, trained on real-world data from 350 million patients, large biomedical knowledge-graphs, and clinical trial data, Katina provides data-driven insights for each simulated protocol. The tool adopts a holistic approach, considering factors such as endpoint success, patient recruitment potential, regulatory compliance, and commercial viability to ensure the selection of the most promising protocol for a specific trial and disease focus.

Orr Inbar, Co-Founder and CEO of QuantHealth, emphasised the game-changing nature of this release for protocol design committees and portfolio optimisation teams. Katina's high-throughput, holistic approach, powered by QuantHealth's generative AI and monte-carlo workflow, enables the simultaneous evaluation of thousands of protocols. This allows stakeholders to assess simulations based on their specific priorities, such as endpoint success, patient recruitment, regulatory approval likelihood, and competitive performance. 

The platform ensures a comprehensive exploration of protocol selection and development strategy, giving voice to all stakeholders involved in the decision-making process.